Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab maintenance versus best standard care alone in advanced urothelial cancer
2015-003262-86Phase 3Completed
- Sponsor
- Pfizer
- Start
- Mar 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of avelumab in transitional cell carcinoma (TCC) and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Pfizer. Primary endpoint: Overall survival. Started Mar 2016; status: completed.
02
Drugs
avelumab
03
Conditions
transitional cell carcinoma (TCC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2015-003262-86.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003262-86.